Literature DB >> 22591143

Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience.

Jonathan Sive1, Kirit M Ardeshna, Simon Cheesman, Franel le Grange, Stephen Morris, Claire Nicholas, Karl Peggs, Paula Statham, Anthony H Goldstone.   

Abstract

Since 2005, University College London Hospital (UCLH) has operated a hotel-based Ambulatory Care Unit (ACU) for hematology and oncology patients requiring intensive chemotherapy regimens and hematopoietic stem cell transplants. Between January 2005 and 2011 there were 1443 patient episodes, totaling 9126 patient days, with increasing use over the 6-year period. These were predominantly for hematological malignancy (82%) and sarcoma (17%). Median length of stay was 5 days (range 1-42), varying according to treatment. Clinical review and treatment was provided in the ACU, with patients staying in a local hotel at the hospital's expense. Admission to the inpatient ward was arranged as required, and there was close liaison with the inpatient team to preempt emergency admissions. Of the 523 unscheduled admissions, 87% occurred during working hours. An ACU/hotel-based treatment model can be safely used for a wide variety of cancers and treatments, expanding hospital treatment capacity, and freeing up inpatient beds for those patients requiring them.

Entities:  

Mesh:

Year:  2012        PMID: 22591143     DOI: 10.3109/10428194.2012.694430

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation.

Authors:  Olle Ringdén; Behnam Sadeghi; Gianluca Moretti; Sigrun Finnbogadottir; Brita Eriksson; Jonas Mattsson; Britt-Marie Svahn; Mats Remberger
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

2.  Letting Kids Be Kids: A Quality Improvement Project to Deliver Supportive Care at Home After High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia [Formula: see text].

Authors:  Lori Ranney; Mary C Hooke; Kathryn Robbins
Journal:  J Pediatr Oncol Nurs       Date:  2020-02-26       Impact factor: 1.636

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.